Literature DB >> 6931470

Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. I. A one year double-blind study of clopenthixol decanoate and flupenthixol palmitate.

S J Dencker, M Lepp, U Malm.   

Abstract

Clopenthixol decanoate and flupenthixol palmitate, both depot neuroleptics belonging to the thioxanthene group, were studied during double-blind conditions for 12 months using four week intervals between injections. The 60 patients included in the study were chronic schizophrenics and treated as outpatients after earlier admission to hospital and rehabilitation training periods. They had all been treated with depot neuroleptics in the last three years and they had been free from relapse for at least 15 months. The main aim with this trial was to study the two depot drugs during maintenance treatment conditions in an outpatient setting. Ten patients dropped out, 7 because of unsatisfactory effect, mainly because only limited dose levels were accepted according to the design. In spite of the earlier long lasting neuroleptic treatment and the good social adaptation in this schizophrenic subgroup there was observed a symptom decrease in all the rating scales even in these symptom poor patients. This improvement in psychopathology with optimal results after half a year seems to be a combined result of the efficient neuroleptics tested and careful monitoring of the drug.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6931470     DOI: 10.1111/j.1600-0447.1980.tb07080.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand Suppl        ISSN: 0065-1591


  9 in total

1.  A review of patient outcomes in pharmacological studies from the psychiatric literature, 1966-1993.

Authors:  Adil E Shamoo; Dianne N Irving; Patricia Langenberg
Journal:  Sci Eng Ethics       Date:  1997-10       Impact factor: 3.525

Review 2.  Zuclopenthixol dihydrochloride for schizophrenia.

Authors:  Edward J Bryan; Marie Ann Purcell; Ajit Kumar
Journal:  Cochrane Database Syst Rev       Date:  2017-11-16

3.  A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients.

Authors:  S J Dencker; I Giös; E Mårtensson; T Nordén; G Nyberg; R Persson; G Roman; O Stockman; K O Svärd
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530

Review 4.  Depot haloperidol decanoate for schizophrenia.

Authors:  S Quraishi; A David
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 5.  Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses.

Authors:  E Coutinho; M Fenton; S Quraishi
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 6.  Depot pipotiazine palmitate and undecylenate for schizophrenia.

Authors:  M Dinesh; A David; S N Quraishi
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18

7.  An open trial of zuclopenthixol in management of acute psychoses : a multicentered study.

Authors:  J Fernandes; P V Pradhan; P Choudhury; S Chatterji; J Pereira; H Shah; H A Bhinderwala; D M Bhadlikar; R Radhakrishanan
Journal:  Indian J Psychiatry       Date:  1999-07       Impact factor: 1.759

8.  Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials.

Authors:  Ying Jiao Zhao; Liang Lin; Monica Teng; Ai Leng Khoo; Lay Beng Soh; Toshiaki A Furukawa; Ross J Baldessarini; Boon Peng Lim; Kang Sim
Journal:  BJPsych Open       Date:  2016-02-05

Review 9.  Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders.

Authors:  Jataveda Mahapatra; Seema N Quraishi; Anthony David; Stephanie Sampson; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2014-06-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.